Cargando…
Generic drugs: Review and experiences from South India
The cost of pharmaceuticals, as a percentage of total healthcare spending, has been rising worldwide. This has resulted in strained national budgets and a high proportion of people without access to essential medications. Though India has become a global hub of generic drug manufacturing, the expect...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535086/ https://www.ncbi.nlm.nih.gov/pubmed/26286613 http://dx.doi.org/10.4103/2249-4863.161305 |
_version_ | 1782385557444231168 |
---|---|
author | Mathew, Philip |
author_facet | Mathew, Philip |
author_sort | Mathew, Philip |
collection | PubMed |
description | The cost of pharmaceuticals, as a percentage of total healthcare spending, has been rising worldwide. This has resulted in strained national budgets and a high proportion of people without access to essential medications. Though India has become a global hub of generic drug manufacturing, the expected benefits of cheaper drugs are not translating into savings for ordinary people. This is in part due to the rise of branded generics, which are marketed at a price point close to the innovator brands. Unbranded generic medicines are not finding their way into prescriptions due to issues of confidence and perception, though they are proven to be much cheaper and comparable in efficacy to branded medicines. The drug inventory of unbranded generic manufacturers fares reasonably when reviewed using the World Health Organization-Health Action International (WHO-HAI) tool for analysing drug availability. Also, unbranded generic medicines are much cheaper when compared to the most selling brands and they can bring down the treatment costs in primary care and family practice. We share our experience in running a community pharmacy for an urban health center in the Pathanamthitta district of Kerala State, which is run solely on generic medicines. The drug availability at the community pharmacy was 73.3% when analyzed using WHO-HAI tool and the savings for the final consumers were up to 93.1%, when compared with most-selling brand of the same formulation. |
format | Online Article Text |
id | pubmed-4535086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-45350862015-08-18 Generic drugs: Review and experiences from South India Mathew, Philip J Family Med Prim Care Health Policy The cost of pharmaceuticals, as a percentage of total healthcare spending, has been rising worldwide. This has resulted in strained national budgets and a high proportion of people without access to essential medications. Though India has become a global hub of generic drug manufacturing, the expected benefits of cheaper drugs are not translating into savings for ordinary people. This is in part due to the rise of branded generics, which are marketed at a price point close to the innovator brands. Unbranded generic medicines are not finding their way into prescriptions due to issues of confidence and perception, though they are proven to be much cheaper and comparable in efficacy to branded medicines. The drug inventory of unbranded generic manufacturers fares reasonably when reviewed using the World Health Organization-Health Action International (WHO-HAI) tool for analysing drug availability. Also, unbranded generic medicines are much cheaper when compared to the most selling brands and they can bring down the treatment costs in primary care and family practice. We share our experience in running a community pharmacy for an urban health center in the Pathanamthitta district of Kerala State, which is run solely on generic medicines. The drug availability at the community pharmacy was 73.3% when analyzed using WHO-HAI tool and the savings for the final consumers were up to 93.1%, when compared with most-selling brand of the same formulation. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4535086/ /pubmed/26286613 http://dx.doi.org/10.4103/2249-4863.161305 Text en Copyright: © Journal of Family Medicine and Primary Care http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Health Policy Mathew, Philip Generic drugs: Review and experiences from South India |
title | Generic drugs: Review and experiences from South India |
title_full | Generic drugs: Review and experiences from South India |
title_fullStr | Generic drugs: Review and experiences from South India |
title_full_unstemmed | Generic drugs: Review and experiences from South India |
title_short | Generic drugs: Review and experiences from South India |
title_sort | generic drugs: review and experiences from south india |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535086/ https://www.ncbi.nlm.nih.gov/pubmed/26286613 http://dx.doi.org/10.4103/2249-4863.161305 |
work_keys_str_mv | AT mathewphilip genericdrugsreviewandexperiencesfromsouthindia |